Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab subcutaneous vs intravenous maintenance in ulcerative colitis
jRCT2080223167Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in autoimmune colitis (3 arms), sponsored by Takeda. Started Apr 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223167.